We had the opportunity to join Smith & Nephew’s (S&N) recent institutional investor roadshow and hear about the introspection that has emerged following the appointment of its new CEO. While endorsing its strategy as a portfolio medical device company, two strategic reviews have identified areas which, when the detail is announced at the Q3 and FY18 results, will enable investors to track S&N’s target of returning to market growth rates.
28 Sep 2018
Smith & Nephew - Turning over that new leaf
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Smith & Nephew - Turning over that new leaf
Smith & Nephew plc (SN:LON) | 1,001 -242.3 (-2.4%) | Mkt Cap: 8,752m
- Published:
28 Sep 2018 -
Author:
Dr Andy Smith -
Pages:
2
We had the opportunity to join Smith & Nephew’s (S&N) recent institutional investor roadshow and hear about the introspection that has emerged following the appointment of its new CEO. While endorsing its strategy as a portfolio medical device company, two strategic reviews have identified areas which, when the detail is announced at the Q3 and FY18 results, will enable investors to track S&N’s target of returning to market growth rates.